Diagnosed with non-radiographic Axial Spondyloarthropathy and various co-morbidities, Tiffany Westrich-Robertson has served as Chief Executive Officer since 2011. Under her leadership, she has spearheaded innovative, award winning projects, all based on patient-identified issues and patient-infused solutions.
In 2015, she led the Ethics of Step Therapy Investigation and authored the associated white paper, which concluded preferred drug recommendations are biased towards patients who meet general patient population standards. As a result, she advocates for legislation that considers individual needs, with focus on access to personalized and precision medicine, access, and value assessments. Additionally, she speaks regulatory to legislators about the importance of biomarker access in non-cancer groups and plans to toggle this work into the new AiArthritis Research Data Bank to gain information to further influence policy.
Tiffany is well-respected in the healthcare community, serving on several committees in both policy and research, including with the American College of Rheumatology, OMERACT (Outcome Measures in Rheumatology), Innovation Value Initiative (IVI), and the Institute for Clinical and Economic Review (ICER) Health Equity and methods revisit committee. Her previous roles included Vice President of Business Development & Project Management at a top architectural firm and college professor, with concentrations in advanced design, Business Development, and Project Management. She was nominated for Teacher of the Year in 2007 and the winner in 2008 as voted on by the student body. She also holds an advisory board seat on the Missouri State University Design Thinking program, helping other executives execute projects in a systematic, yet creatively innovative, manner.
